# **Special Issue**

# Retroviral Capsid: Assembly, Maturation and Interaction with Host and Antiviral Factors

## Message from the Guest Editors

The retroviral capsid (CA) protein is involved in multiple steps in the virus life cycle. In virus particle assembly, the CA protein is the key driver in forming the hexameric lattice found in immature particles, and following virus maturation forms a CA core in mature virus particles. Following infection, the CA protein is involved in core trafficking, uncoating, reverse transcription, and nuclear entry. CA is recognized by numerous cellular proteins, including those that can either facilitate or restrict CA core stability, trafficking, and/or nuclear entry. Mutation of CA and targeting by novel antiretroviral compounds can perturb core stability and particle infectivity. Structure-function analysis of CA variants and CA bound to small molecules have provided further insights into CA function and the mechanism of small molecule antiviral action. This special issue aims to highlight the cutting-edge advancements in methods and research on the retroviral CA protein, spanning topics such as CA trafficking and nuclear import, core stability, reverse transcription, virion assembly, maturation, and interactions with the host proteins and antiviral molecules.

## **Guest Editors**

Dr. Wei Zhang

Prof. Dr. Louis M. Mansky

Dr. Nathaniel Talledge

Deadline for manuscript submissions closed (31 October 2023)



# Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/116460

Viruses Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 viruses@mdpi.com

mdpi.com/journal/

viruses





# Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



viruses



# About the Journal

# Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

## Editor-in-Chief

Dr. Eric O. Freed HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).